Country

Clinical trials in Greece

Active obesity and GLP-1 studies with at least one location in Greece.

33active studies

20recruiting now

32countries represented

229largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

Overweight, ObesityCondition

Cagrilintide, Placebo cagrilintideTreatment

Greece, Hungary36 locations

Novo Nordisk A/SSponsor

Updated 2026-09-04 · NCT07745504See eligibility →

Recruiting nowPhase 3

Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

Overweight, ObesityCondition

Semaglutide, PlaceboTreatment

Belgium, Bulgaria62 locations

Novo Nordisk A/SSponsor

Updated 2026-08-18 · NCT07770841See eligibility →

Recruiting nowPhase 3

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

Obesity, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Australia, Bulgaria81 locations

Novo Nordisk A/SSponsor

Updated 2026-08-17 · NCT07509307See eligibility →

Recruiting nowPhase 3

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Obesity, OverweightCondition

ASC30 tablets A1, PlaceboTreatment

Czechia, Germany136 locations

Ascletis Pharma (China) Co., LimitedSponsor

Updated 2026-08-14 · NCT07743450See eligibility →

Recruiting nowPhase 3

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

ASC30 tablets A1, PlaceboTreatment

Canada, Czechia120 locations

Ascletis Pharma (China) Co., LimitedSponsor

Updated 2026-08-14 · NCT07743463See eligibility →

Recruiting nowNot applicable

Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists.

Obesity (Disorder), Anti-obesity AgentsCondition

Semaglutide or TirzepatideTreatment

Greece1 locations

National and Kapodistrian University of AthensSponsor

Updated 2026-07-10 · NCT07653412See eligibility →

Recruiting nowPhase 3

A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

Obesity, Knee Osteoarthritis (OA)Condition

NNC0487-0111, Placebo (matched to NNC0487-0111 )Treatment

Australia, Bulgaria82 locations

Novo Nordisk A/SSponsor

Updated 2026-07-09 · NCT07481630See eligibility →

Recruiting nowNot applicable

Long-term Adaptations of Skeletal Muscle After Hybrid Training

Obesity & OverweightCondition

Exercise training, Control groupTreatment

Greece1 locations

University of ThessalySponsor

Updated 2026-06-12 · NCT07341711See eligibility →

Recruiting nowNot applicable

Impact of GLP-1 Receptor Agonists on Dry Eye Disease in Patients With Type 2 Diabetes Mellitus and Obesity

Dry Eye Disease (DED), Diabete MellitusCondition

Intervention not listedTreatment

Greece1 locations

Attikon HospitalSponsor

Updated 2026-06-02 · NCT07605572See eligibility →

Recruiting nowNot applicable

Exercise Training and Vitamin D Metabolism

Obesity & Overweight, Vitamin DCondition

Exercise training, ControlTreatment

Greece1 locations

University of ThessalySponsor

Updated 2026-05-26 · NCT07300332See eligibility →

Recruiting nowNot applicable

Evaluation of the Stress Response in Anesthesia Use Inhalation Anesthetic (Desflurane) Versus TIVA for Bariatric Surgery

Opioid Use, Bariatric Surgery CandidateCondition

opioid free anesthesia, Opiod Free Anesthesia with TCI ELEVELDTreatment

Greece1 locations

G.Gennimatas General HospitalSponsor

Updated 2026-05-06 · NCT07568938See eligibility →

Recruiting nowNot applicable

Effect of GLP-1 Receptor Agonists on Body Composition in Obesity: The Role of Dietary Protein Consumption in Muscle Mass Maintenance

ObesityCondition

High Protein Dietary Intervention, Control (Standard Mediterranean Diet Counseling)Treatment

Greece2 locations

Hellenic Mediterranean UniversitySponsor

Updated 2026-04-02 · NCT07495904See eligibility →

Recruiting nowNot applicable

High Phenolic Olive Oil for Enhancing Metabolic Health: a Randomized-controlled Trial in Patients With cEntral Obesity (HOPE)

Adults, Overweight , ObesityCondition

Low phenolic olive oil, High phenolic olive oilTreatment

Greece1 locations

University of PeloponneseSponsor

Updated 2026-03-03 · NCT07445503See eligibility →

Recruiting nowNot applicable

Comparison of Genotype-Based Dietary Counseling Versus Standard Dietary Counseling on Weight Loss and Fat Mass Reduction

Overweight, Overweight and ObesityCondition

Genotype-Based Dietary Counseling, Standard Dietary CounselingTreatment

Greece1 locations

Metropolitan CollegeSponsor

Updated 2026-01-28 · NCT07368777See eligibility →

Recruiting nowNot applicable

Tirzepatide vs Liraglutide in Bone

Obesity (Disorder)Condition

Intervention not listedTreatment

Greece1 locations

National and Kapodistrian University of AthensSponsor

Updated 2026-01-21 · NCT07094568See eligibility →

Recruiting nowNot applicable

Redox Status and Exercise Training-induced Adaptations

Overweight (BMI > 25), ObesityCondition

N Acetyl L Cysteine, PlaceboTreatment

Greece1 locations

University of ThessalySponsor

Updated 2025-12-16 · NCT07196852See eligibility →

Recruiting nowNot applicable

Better4All Personalized Intervention Pilot Study

Obesity PreventionCondition

BETTER4U Mobile App and Wearable Use (End-User Group), BETTER4U Intervention Platform Testing (Implementer Group)Treatment

Cyprus, France7 locations

Harokopio UniversitySponsor

Updated 2025-08-13 · NCT07120802See eligibility →

Recruiting nowNot applicable

Supplemental High Flow Oxygen to Reduce Infections in Obese Gynecological Cancer Patients

Supplemental Oxygen, Gynecological CancerCondition

Supplemental oxygen therapyTreatment

Greece1 locations

National and Kapodistrian University of AthensSponsor

Updated 2025-01-17 · NCT06780813See eligibility →

Recruiting nowNot applicable

Global Research Initiative for Patients Screening on MASH

MASH, MASLDCondition

Intervention not listedTreatment

Belgium, Czechia13 locations

Julius ClinicalSponsor

Updated 2024-08-01 · NCT05651724See eligibility →

Recruiting nowNot applicable

The European NAFLD Registry

NAFLD, NASHCondition

Intervention not listedTreatment

Belgium, Finland37 locations

Newcastle UniversitySponsor

Updated 2023-01-06 · NCT04442334See eligibility →

Opening soonNot applicable

Chrono-Fasting in Overweight and Obese Adolescents

ObesityCondition

Early TRF, late TRFTreatment

Greece1 locations

University of ThessalySponsor

Updated 2026-08-12 · NCT07759414See eligibility →

Opening soonNot applicable

Human Pilot Study for the Investigation of the Role of Bilberry and Olive Bioactives on Oxidative Stress Parameters and Inflammatory Markers.

Prediabetes, Obesity & OverweightCondition

supplementation, foodTreatment

Greece1 locations

National and Kapodistrian University of AthensSponsor

Updated 2026-06-22 · NCT07659028See eligibility →

Opening soonNot applicable

AI-INFORMED PEER-MENTORING BEHAVIORAL INTERVENTION FOR OBESITY AND CARDIOVASCULAR DISEASE PRIMARY PREVENTION IN YOUTH

Obesity (Disorder)Condition

AI-informed behavioral intervention, Standard behavioral interventionTreatment

Greece, Italy3 locations

Aikaterini KaraivazoglouSponsor

Updated 2026-04-14 · NCT07505459See eligibility →

Opening soonNot applicable

Better4All Personalized Intervention

Obesity PreventionCondition

Personalized lifestyle recommendations based on artificial intelligence (AI) and polygenic risk scores (PRS), Standard care: lifestyle counselling, healthy eating leaflet, and hyocaloric diet targeting ≥5% weight loss in 6 months.Treatment

Cyprus, France7 locations

Harokopio UniversitySponsor

Updated 2025-05-30 · NCT06997510See eligibility →

Opening soonPhase 2

Perioperative Music in Obese Patients Under Spinal Anesthesia

Obesity, AdolescentCondition

Music intervention, Midazolam (sedative)Treatment

Greece3 locations

Asklepieion Voulas General HospitalSponsor

Updated 2025-02-19 · NCT06835101See eligibility →

Active, not recruitingNot applicable

Predictive Value of Nutritional and Inflammatory Indices for Postoperative Complications After Bariatric Surgery

Obesity (BMI > 35), Morbid ObesityCondition

Bariatric SurgeryTreatment

Greece1 locations

G.Gennimatas General HospitalSponsor

Updated 2026-08-06 · NCT07747168See eligibility →

Active, not recruitingPhase 3

A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

Diabetes Mellitus, Type 2Condition

Semaglutide, Placebo (semaglutide)Treatment

Brazil, Bulgaria229 locations

Novo Nordisk A/SSponsor

Updated 2026-08-04 · NCT03811561See eligibility →

Active, not recruitingPhase 4

STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss

ObesityCondition

SemaglutideTreatment

Belgium, Canada93 locations

Novo Nordisk A/SSponsor

Updated 2026-06-02 · NCT06571383See eligibility →

Active, not recruitingPhase 3

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

HypertensionCondition

Orforglipron, PlaceboTreatment

Argentina, China100 locations

Eli Lilly and CompanySponsor

Updated 2026-05-29 · NCT06948422See eligibility →

Active, not recruitingPhase 3

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

Hypertension, Overweight or ObesityCondition

Orforglipron, PlaceboTreatment

Argentina, China99 locations

Eli Lilly and CompanySponsor

Updated 2026-05-29 · NCT06948435See eligibility →

Active, not recruitingPhase 3

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

HypertensionCondition

Orforglipron, PlaceboTreatment

Argentina, China99 locations

Eli Lilly and CompanySponsor

Updated 2026-05-29 · NCT06952530See eligibility →

Active, not recruitingPhase 3

A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

Type 1 Diabetes, ObesityCondition

Tirzepatide, PlaceboTreatment

Argentina, Brazil79 locations

Eli Lilly and CompanySponsor

Updated 2026-02-17 · NCT06962280See eligibility →

Active, not recruitingNot applicable

Multinational Point Prevalence Study on the Management of Diabesity in Hospitals

Diabetes Mellitus, ObesityCondition

Routine care for people with diabetes, with or without obesity, in the hospital settingTreatment

Austria, Czechia8 locations

Medical University of ViennaSponsor

Updated 2025-05-08 · NCT06680674See eligibility →

Related countries

United States1,107 China326 Canada158 France110 Spain98 Germany95

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.